Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07170462 · ClinicalTrials.gov registry record · Early Phase 1
Cranberry and Gut Health in Crohn's Disease
A Early Phase 1 study of Crohn Disease and Crohn Disease (CD), sponsored by Ana Maldonado-Contreras.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT07170462 is a Early Phase 1 study of Crohn Disease and Crohn Disease (CD) that is actively recruiting participants, run by Ana Maldonado-Contreras. The registered enrollment target is 50 participants, below the 205-participant average among 71 other Crohn Disease trials with a reported enrollment target (76% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07170462, a Early Phase 1 study of Crohn Disease and Crohn Disease (CD), is actively recruiting participants, sponsored by Ana Maldonado-Contreras.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is investigating whether a cranberry-based dietary supplement, rich in polyphenols and fiber, can enhance gut health in individuals with Crohn's disease. People with Crohn's disease often have an imbalance in their gut microbiome (the community of bacteria in the gut). Previous research suggests that cranberry compounds may help support beneficial gut bacteria. In this study, adults with Crohn's disease will be randomly assigned to one of two groups: one group will receive a cranberry supplement to take once daily for 10 weeks, and the other group will receive a placebo (a supplement with no active ingredients). All participants will be asked to complete online questionnaires and collect samples of their blood, urine, and stool at four time points over a total of 15 weeks. These samples will help researchers understand how the cranberry supplement affects the gut microbiome, inflammation, and overall health. Participation is voluntary, and participants can withdraw from the study at any time. The results of this study may help identify new diet-based approaches to improve gut health in individuals with Crohn's disease.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Placebo
- DRUG Cranberry powder
Study Locations (1)
Massachusetts
- UMASS medical center - Worcester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2025-10-29 |
| Est. Completion | 2026-09-15 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07170462
The ClinicalTrials.gov registry entry for NCT07170462 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 205-participant average among 71 other Crohn Disease trials with a reported enrollment target (76% lower). The listed sponsor is Ana Maldonado-Contreras, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Crohn Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07170462 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT07170462 about?
NCT07170462 is a clinical study titled "Cranberry and Gut Health in Crohn's Disease". This study is investigating whether a cranberry-based dietary supplement, rich in polyphenols and fiber, can enhance gut health in individuals with Crohn's disease. People with Crohn's disease often have an imbalance in their gut microbiome (the community of bacteria in the gut). Previous research s...
What is the current status of trial NCT07170462?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 50 participants. The study started on 2025-10-29. Estimated completion is 2026-09-15.
What conditions does trial NCT07170462 study?
This clinical trial studies the following conditions: Crohn Disease, Crohn Disease (CD).
What interventions are being tested in trial NCT07170462?
The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), Cranberry powder (DRUG).
Who is sponsoring clinical trial NCT07170462?
This trial is sponsored by Ana Maldonado-Contreras, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07170462 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Crohn Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Effect of Statins on Crohn's Disease
RECRUITING · Early Phase 1
-
Oral Administration of MB-102 Versus Dual Sugar Testing for Gut Permeability
COMPLETED · Early Phase 1
-
Stelara and Tremfya Pregnancy Exposure Registry OTIS Autoimmune Diseases in Pregnancy Project
RECRUITING
-
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
RECRUITING · Phase 1
-
Treat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic Remission
RECRUITING · NA
-
Low Dose IL-2 for the Treatment of Crohn's Disease
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.